Alexander is an investment manager of the Boehringer Ingelheim Venture Fund and currently serves as a board member of Tacalyx GmbH and AIgnostics GmbH.
Alexander joined Boehringer Ingelheim in 2012 in Translational Medicine and in 2014 was appointed Global Head of the Translational Medicine and Biomarker Experts group responsible for translational medicine and biomarker aspects of novel pharmaceutical compounds. Prior to joining Boehringer Ingelheim, he worked at a biotech start-up in California and a major US pharmaceutical company in a variety of roles in clinical drug development. His focus was on novel drugs and imaging tracers in the cardiovascular and metabolic diseases areas. He also conducted academic research on myocardial perfusion and stress echocardiography at the University of Oxford, UK. Alexander is a physician, who received his medical degree from the University of Bonn, Germany.